Thomson Reuters

The Prous Science Integrity® portal contains data on more than 275,000 compounds with demonstrated biological activity and almost 100,000 patent family records.

Prous Science Integrity incorporates twelve key knowledge areas related to drug research and development: drugs and biologics, targets and pathways, genomics, biomarkers, organic synthesis, experimental pharmacology, pharmacokinetics/metabolism, clinical studies, disease briefings, companies and research institutions, literature, and patents.

Utilizes the latest technology to host and stream drug R&D science news, animations, presentations, webcasts, and company and research institution profiles direct to your desktop.

With Prous Science Integrity, you can:

• Access recent and relevant information at a click
• Drive higher-quality results in drug research and development
• Foster better decision-making
• Develop new approaches to information retrieval and analysis
• Manage data quickly and easily

Why choose Prous Science Integrity?

Prous Science Integrity incorporates twelve key knowledge areas related to drug research and development: Drugs & Biologics, Targets & Pathways, Genomics, Biomarkers, Organic Synthesis, Experimental Pharmacology, Pharmacokinetics/Metabolism, Clinical Studies, Disease Briefings, Companies & Research Institutions, Literature, and Patents.

• Drugs & Biologics: essential chemical and pharmacological information, and the development status of bioactive compounds in the drug pipeline.
• Targets & Pathways: target-based approaches to disease diagnosis and therapeutic intervention.
  Genomics: comprehensive genomics/proteomics  data establishing the foundation that will lead from gene to disease.
• Organic Synthesis: routes of synthesis (schemes, intermediates, reagents, end products) for drugs currently on the market or in development.
• Experimental Pharmacology: data from experimental studies that delineate drug/receptor and enzyme/target cell interactions.
• Pharmacokinetics/Metabolism: data from experimental and clinical studies that delineate the absorption, distribution, metabolism and excretion (ADME) profile of a drug.
• Clinical Studies: comprehensive information on clinical trials of drugs currently under study or in use in humans.
• Disease Briefings: dynamic executive summaries on the current status of and future trends in drug therapy.
• Companies & Research Institutions: essential information on public and private companies, academic centers and research institutions active in the fields of pharmaceuticals and biotechnology.
• Literature: references to current biomedical literature, abstracts and proceedings from congresses and symposia and company communications.
• Patents: references to the most recent patent literature reflecting drug research activity throughout the world.